We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
VSQM
526
V-Square Quantitative Management
Illinois
– -$166K -4,618 Closed
BIG
527
Brooklyn Investment Group
New York
– -$84.3K -2,341 Closed
T
528
Transce3nd
Texas
– -$79.4K -2,203 Closed
AGWCA
529
Annis Gardner Whiting Capital Advisors
Florida
– -$33.3K -923 Closed
TSMHT
530
Thurston Springer Miller Herd & Titak
Indiana
– -$14.2K -393 Closed
WTC
531
WhitTier Trust Company
Nevada
– -$12.6K -350 Closed
WT
532
Whittier Trust
California
– -$8.72K -242 Closed
NC
533
NewSquare Capital
Pennsylvania
– -$6.09K -169 Closed
CIA
534
Cape Investment Advisory
Georgia
– -$1.3K -36 Closed
SO
535
Sierra Ocean
California
– -$1.19K -33 Closed
TPWA
536
Twin Peaks Wealth Advisors
California
– -$820 -23 Closed
SC
537
Stephens Consulting
Michigan
– -$721 -20 Closed
KIM
538
Kestra Investment Management
Texas
– -$592 -19 Closed
SFCL
539
Strengthening Families & Communities LLC
Massachusetts
– -$292 -8 Closed
AAS
540
Ameritas Advisory Services
Nebraska
– -$252 -7 Closed
CCM
541
Cloud Capital Management
Washington
– +$217 +6 New
18 19 20 21
22

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.